What is Valley Fever meningitis. How is coccidioidal meningitis diagnosed. What are the complications of untreated coccidioidal meningitis. How is Valley Fever meningitis treated. Why is lifelong treatment recommended for coccidioidal meningitis.

Understanding Coccidioidal Meningitis: A Serious Complication of Valley Fever

Coccidioidal meningitis (CM) is a severe complication of Valley Fever, caused by the spread of Coccidioides fungi to the central nervous system (CNS). This condition represents the most dangerous form of extrapulmonary dissemination in Valley Fever cases. Due to its potentially life-threatening nature, early diagnosis and prompt treatment are crucial for improving patient outcomes.

Key Symptoms of Coccidioidal Meningitis

Patients with suspected or previously diagnosed coccidioidomycosis should be alert to the following symptoms, which may indicate the development of CM:

• Persistent headache
• Blurry vision
• Photophobia (sensitivity to light)
• Meningismus (neck stiffness)
• Cognitive decline
• Changes in hearing
• Focal neurologic deficits

The presence of these symptoms warrants immediate medical attention and further diagnostic testing.

Diagnostic Approach for Coccidioidal Meningitis

Accurately diagnosing CM is essential for initiating appropriate treatment. The diagnostic process typically involves several steps:

Lumbar Puncture and CSF Analysis

A lumbar puncture is performed to obtain cerebrospinal fluid (CSF) for analysis. This procedure is crucial for patients exhibiting CNS symptoms. Recent studies have shown that routine CSF analysis is not necessary for asymptomatic patients, even if they belong to at-risk groups.

CSF Characteristics in Coccidioidal Meningitis

Typical findings in CSF analysis of CM patients include:

• Elevated white blood cell count with mixed or lymphocytic pleocytosis
• High protein levels (sometimes measurable in g/dL rather than mg/dL)
• Low glucose levels

Serologic Testing and Culture

The diagnosis of CM is confirmed through positive serologic testing (ID/CF) or culture of the CSF. These tests are specific for detecting Coccidioides infection in the CNS.

Imaging Studies

While not diagnostic on their own, imaging studies play a crucial role in evaluating complications associated with CM. They can help identify hydrocephalus, cerebral ischemia, infarction, or other structural changes in the brain.

The Critical Importance of Treating Coccidioidal Meningitis

Untreated CM is invariably fatal, underscoring the critical need for prompt and effective intervention. Historical data paints a grim picture of the disease’s natural course:

• In a series reported by Vincent et al., all 17 untreated CM patients died within 31 months.
• Combined statistics from five reports showed that 91% of 117 untreated CM patients died within one year, and none survived beyond two years.

While modern antifungal treatments have significantly improved survival rates, CM still carries substantial morbidity due to disease complications, treatment-related side effects, and the need for long-term management.

Life-Threatening Complications of Coccidioidal Meningitis

CM can lead to several severe complications that contribute to its high morbidity and mortality rates:

• Hydrocephalus
• CNS vasculitis
• Cerebral ischemia and infarction
• Vasospasm
• Cerebral hemorrhage
• Basilar meningitis
• Spinal cord involvement

Managing Hydrocephalus in CM Patients

Hydrocephalus, a common complication of CM, often requires the placement of a ventricular shunt for decompression. However, these shunts can lead to additional challenges:

• Secondary infections
• Obstruction due to persistent coccidioidomycosis
• Formation of abdominal pseudocysts (when shunts are placed in the abdominal cavity)

Patients may need multiple shunt revisions, and persistent problems with shunt function may indicate the need for alternative antifungal therapies.

Current Treatment Approaches for Coccidioidal Meningitis

The management of CM has evolved significantly with the advent of newer antifungal medications. Current treatment strategies focus on oral azole antifungals, particularly fluconazole.

Fluconazole: The Preferred First-Line Treatment

Oral fluconazole is now the preferred treatment for CM. Key points about fluconazole therapy include:

• Initial dosing typically ranges from 800 to 1200 mg per day.
• This higher dosage is necessary due to the need for CNS penetration.
• Clinical studies have shown a response rate of approximately 79% with fluconazole treatment.

Amphotericin B: Historical Treatment and Current Role

Before the development of azole antifungals, amphotericin B deoxycholate (AmB) was the only available treatment for CM. However, its use was limited by several factors:

• Ineffectiveness when administered intravenously for CM
• Requirement for intrathecal (IT) administration
• Challenges and toxicities associated with IT administration

While AmB is rarely used as initial therapy today, lipid formulations have shown success in salvage therapy scenarios.

The Necessity of Lifelong Treatment for Coccidioidal Meningitis

One of the most critical aspects of CM management is the need for lifelong antifungal therapy. This recommendation is based on clinical experience and research findings:

• A small study showed a 78% relapse rate when therapy was discontinued.
• Symptoms typically resolve within 4-8 months of starting treatment.
• CSF abnormalities may persist longer, especially in patients with shunts.

The high relapse rate and potential for severe complications make continuous, lifelong treatment essential for most CM patients.

Monitoring Treatment Response and Long-Term Management

Assessing a patient’s response to CM treatment requires ongoing evaluation and clinical judgment. Favorable signs of treatment response include:

• Return to premorbid functioning
• Decreasing complement fixation (CF) titers
• Excellent adherence to medical care and therapy

Challenges in Assessing Treatment Efficacy

Some patients with chronic CM may experience refractory illness, characterized by poor recovery or exceptionally slow improvement. In these cases, a combination of approaches is necessary to assess treatment efficacy:

• Serial clinical evaluations
• Monitoring of serologic markers
• Repeated CSF analysis

The Importance of Patient Adherence

Given the necessity of lifelong treatment, patient adherence to therapy is crucial. Healthcare providers should prioritize:

• Regular adherence counseling
• Education about the importance of continuous treatment
• Monitoring for and managing medication side effects

By ensuring patient understanding and addressing concerns, healthcare providers can improve long-term outcomes for individuals with CM.

Emerging Treatments and Future Directions in Coccidioidal Meningitis Management

While current treatments have significantly improved outcomes for CM patients, research continues to explore new therapeutic options and management strategies. Some areas of ongoing investigation include:

Novel Antifungal Agents

Researchers are exploring new antifungal compounds that may offer improved efficacy or reduced side effects compared to current options. These include:

• New azole derivatives with enhanced CNS penetration
• Novel classes of antifungal drugs targeting specific aspects of fungal metabolism
• Combination therapies that may enhance treatment efficacy

Immunomodulatory Approaches

Given the complex interaction between Coccidioides and the host immune system, immunomodulatory therapies are an area of interest. Potential approaches include:

• Targeted immune-boosting therapies to enhance fungal clearance
• Modulation of inflammatory responses to reduce tissue damage
• Vaccine development for prevention or therapeutic use

Advanced Diagnostic Techniques

Improving the speed and accuracy of CM diagnosis remains a priority. Emerging diagnostic approaches include:

• Advanced molecular testing methods for rapid fungal identification
• Biomarker discovery for early detection of CNS involvement
• Improved imaging techniques for detecting subtle CNS changes

Personalized Treatment Strategies

As our understanding of CM pathogenesis and host-pathogen interactions grows, there is increasing interest in developing personalized treatment approaches. This may involve:

• Genetic profiling to predict treatment response and risk of complications
• Tailored antifungal regimens based on individual patient characteristics
• Adaptive treatment protocols that evolve with the patient’s response

These emerging areas of research hold promise for improving the management of CM and potentially reducing the need for lifelong therapy in some patients.

The Role of Patient Education and Support in Coccidioidal Meningitis Management

Effective management of CM extends beyond medical treatment to encompass comprehensive patient education and support. Key aspects of this approach include:

Understanding the Disease Process

Patients and their families should be educated about:

• The nature of Coccidioides infection and its potential for CNS involvement
• The importance of early symptom recognition and prompt medical attention
• The chronic nature of CM and the necessity for long-term management

Treatment Adherence Strategies

Given the critical importance of lifelong therapy, patients should be provided with tools and strategies to maintain treatment adherence:

• Medication reminders and tracking systems
• Education about potential drug interactions and side effects
• Regular check-ins with healthcare providers to address concerns and adjust treatment as needed

Psychosocial Support

Living with a chronic condition like CM can have significant psychological impacts. Support should include:

• Access to mental health resources and counseling
• Connection with support groups or patient advocacy organizations
• Strategies for managing the emotional and social aspects of chronic illness

Lifestyle Modifications

Patients should be advised on lifestyle changes that may support their overall health and potentially impact disease management:

• Nutrition and exercise recommendations
• Stress management techniques
• Avoidance of environmental factors that may exacerbate symptoms or increase infection risk

By incorporating these elements into the overall management plan, healthcare providers can help patients with CM achieve better long-term outcomes and improved quality of life.

The Importance of Ongoing Research in Coccidioidal Meningitis

Despite advances in treatment, CM remains a challenging condition with significant morbidity and mortality. Ongoing research is crucial for improving our understanding of the disease and developing more effective management strategies. Key areas of focus include:

Epidemiological Studies

Continued research into the epidemiology of CM can help identify at-risk populations and inform prevention strategies. This includes:

• Monitoring changes in disease distribution and incidence
• Identifying environmental and host factors that influence disease progression
• Assessing the impact of climate change on Coccidioides distribution and virulence

Pathogenesis Research

A deeper understanding of how Coccidioides invades the CNS and causes meningitis can lead to new therapeutic targets. Areas of investigation include:

• Mechanisms of fungal dissemination to the CNS
• Host immune responses in the context of CM
• Factors influencing the development of antifungal resistance

Clinical Trials

Ongoing and future clinical trials are essential for evaluating new treatments and management approaches. These may include:

• Studies of novel antifungal agents or combination therapies
• Trials of immunomodulatory treatments
• Investigations into optimal treatment durations and discontinuation strategies

Long-Term Outcome Studies

Given the chronic nature of CM, long-term studies are crucial for understanding the full impact of the disease and its treatment. These studies can assess:

• Long-term neurological outcomes in treated patients
• Quality of life measures over extended periods
• The cumulative effects of lifelong antifungal therapy

By continuing to invest in research across these areas, the medical community can work towards improving outcomes for patients with CM and potentially developing curative treatments in the future.

Coccidioidal Meningitis | UC Davis Center for Valley Fever

Skip to main content

Center for Valley Fever

News | Careers | Giving | UC Davis Health

1. UC Davis Health
2. Center for Valley Fever
3. About Valley Fever

The most deleterious extrapulmonary dissemination is the spread of Coccidioides spp. to the central nervous system (CNS) causing meningitis. A lumbar puncture with analysis of cerebrospinal fluid (CSF) should be done in any patient with suspected or previously diagnosed coccidioidomycosis presenting with a headache, blurry vision, photophobia, meningismus, decline in cognition, hearing changes, and focal neurologic deficit. As illustrated in a recent retrospective study there is no evidence to support routine CSF analysis in patients in at-risk groups (age, ethnicity, CF titer, etc. ) if they do not have CNS symptoms (1). The diagnosis of CM is based on a positive serologic testing (ID/CF) or culture of CSF. CSF analysis typically shows an elevated white blood cell count with a mixed or lymphocytic pleocytosis, a high level of protein (sometimes measurable in g/dL rather than mg/dL), and a low level of glucose. Imaging studies are helpful in evaluating complications associated with meningitis. Initial features of illness may be difficult to distinguish from other etiologies without detailed testing, notably tuberculosis and even autoimmune illnesses.

When left untreated, CM is uniformly fatal (2). In a historical series reported by Vincent et al, before the availability of antifungals, seventeen patients with CM were followed all of whom died within 31 months (2). This review also commented on the combined survival statistics described in five reports of 117 patients where 91% of patients with CM died within one year and all died within 2 years. Though the fatality has improved with the use of AmB and azoles, morbidity is still substantial due to complications from the disease, devices used for treatment management, and side effects of the medications as much higher recommended doses are necessary for prolonged period of time (3).

The most common life-threatening complications of meningitis include hydrocephalus, CNS vasculitis, cerebral ischemia, infarction, vasospasm and hemorrhage. Basilar meningitis and spinal cord involvement may also be encountered. In patients with hydrocephalus, a ventricular shunt is necessary for decompression. Such shunts, often placed distally into the abdominal cavity may develop secondary infections, obstruction due to persistent coccidioidomycosis, and/or abdominal pseudocysts (4). It is not uncommon for patients to require multiple shunt revisions. As illustrated in several case reports, repeated obstruction of the shunt and isolation of fungus should alert one to seek alternate antifungal therapy. Some clinicians have used steroids for vasculitis though this is considered anecdotal.

For treatment of CM, most clinicians prefer therapy with oral fluconazole (5). Although the dose studied in an uncontrolled clinical trial was 400 mg, it is common to begin therapy with 800 to 1200 mg per day of fluconazole (3, 6). Prior to the advent of azoles, amphotericin B deoxycholate (AmB) was the only drug of choice but was ineffective when given intravenously and required frequent administrations via the intrathecal (IT) route. Due to challenges of administration, toxicity associated with this route and lack of experience in utilizing this method, current practitioners seldom resort to recommending AmB as initial therapy although lipid formulations have been used in the salvage setting successfully (7). Though there are no trials comparing IT AmB and fluconazole, the response rate of IT AmB has ranged from 51%-100% in studies published before 1986 and with fluconazole the rate is near 79% (6, 8). With fluconazole symptoms resolve within 4-8 months though there is a delay in normalization of CSF abnormalities which may persist in the presence of a shunt. Based on clinical experience and due to an extremely high relapse of 78% noted in a small series when therapy is discontinued, lifelong treatment with azoles is recommended (9).

Assessing a patient’s response to therapy is primarily a matter of serial evaluation and clinical judgment. Favorable signs include return to premorbid functioning, decreasing CF titers, and excellent adherence to medical care and therapy. Some patients with chronic meningitis have refractory illness with poor recovery or exceptionally slow improvement. A combination of serology and repeated CSF evaluation may be necessary to assess microbiologic and serologic improvement. Adherence counseling, assessment of drug-drug interactions, therapeutic drug monitoring, and consideration of alternative antifungal therapy may be necessary. For CM patients who are failing treatment and/or have refractory coccidioidal disease, salvage regimens may be necessary. Both voriconazole and posaconazole have been used in this situation, with a growing body of case series and clinical experience to support their use.

REFERENCES

1. Thompson G, 3rd, Wang S, Bercovitch R, et al. Routine CSF Analysis in Coccidioidomycosis Is Not Required. PloS one 2013; 8(5): e64249.
2. Vincent T, Galgiani JN, Huppert M, Salkin D. The natural history of coccidioidal meningitis: VA-Armed Forces cooperative studies, 1955-1958. Clin Infect Dis 1993; 16(2): 247-54.
3. Johnson RH, Einstein HE. Coccidioidal meningitis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006; 42(1): 103-7.
4. Hibbett DS, Binder M, Bischoff JF, et al. A higher-level phylogenetic classification of the Fungi. Mycol Res 2007; 111(Pt 5): 509-47.
5. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41(9): 1217-23.
6. Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Annals of internal medicine 1993; 119(1): 28-35.
7. Mathisen G, Shelub A, Truong J, Wigen C. Coccidioidal meningitis: clinical presentation and management in the fluconazole era. Medicine 2010; 89(5): 251-84.
8. Bouza E, Dreyer JS, Hewitt WL, Meyer RD. Coccidioidal meningitis. An analysis of thirty-one cases and review of the literature. Medicine 1981; 60(3): 139-72.
9. Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Annals of internal medicine 1996; 124(3): 305-10.

Valley fever – Symptoms & causes

Overview

Valley fever is a fungal infection caused by coccidioides (kok-sid-e-OY-deze) organisms. It can cause signs and symptoms such as a fever, cough and tiredness.

Two coccidioides fungi species cause valley fever. These fungi are commonly found in soil in specific regions. The fungi’s spores can be stirred into the air by anything that disrupts the soil, such as farming, construction and wind.

People can then breathe the fungi into their lungs. The fungi can cause valley fever, also known as acute coccidioidomycosis (kok-sid-e-oy-doh-my-KOH-sis). Mild cases of valley fever usually resolve on their own. In more-severe cases, doctors treat the infection with antifungal medications.

Products & Services

Symptoms

Valley fever is the initial form of coccidioidomycosis infection. This initial, acute illness can develop into a more serious disease, including chronic and disseminated coccidioidomycosis.

Acute coccidioidomycosis (valley fever)

The initial, or acute, form of coccidioidomycosis is often mild, with few or no symptoms. Signs and symptoms occur one to three weeks after exposure. They tend to be similar to flu symptoms. Symptoms can range from minor to severe, including:

• Fever
• Cough
• Tiredness
• Shortness of breath
• Headache
• Chills
• Night sweats
• Joint aches and muscle soreness
• Red, spotty rash, mainly on lower legs but sometimes on the chest, arms and back

If you don’t become ill or have symptoms from valley fever, you may only find out you’ve been infected later. You may find out when you have a positive skin or blood test or when small areas of residual infection in the lungs (nodules) show up on a routine chest X-ray. The nodules typically don’t cause problems, but they can look like cancer on X-rays.

If you develop symptoms, especially severe ones, the course of the disease is highly variable. It can take months to fully recover. Fatigue and joint aches can last even longer. The disease’s severity depends on several factors, including your overall health and the number of fungus spores you inhale.

Chronic coccidioidomycosis

If the initial coccidioidomycosis infection doesn’t completely resolve, it may progress to a chronic form of pneumonia. This complication is most common in people with weakened immune systems.

Signs and symptoms include:

• Low-grade fever
• Weight loss
• Cough
• Chest pain
• Blood-tinged sputum (matter discharged during coughing)
• Nodules in the lungs

Disseminated coccidioidomycosis

The most serious form of the disease, disseminated coccidioidomycosis, is uncommon. It occurs when the infection spreads (disseminates) beyond the lungs to other parts of the body. Most often these parts include the skin, bones, liver, brain, heart, and the membranes that protect the brain and spinal cord (meninges).

Signs and symptoms of disseminated disease depend on the body parts affected and may include:

• Nodules, ulcers and skin lesions that are more serious than the rash that sometimes occurs with initial infection
• Painful lesions in the skull, spine or other bones
• Painful, swollen joints, especially in the knees or ankles
• Meningitis — an infection of the membranes and fluid surrounding the brain and spinal cord

When to see a doctor

Seek medical care if you are over 60, have a weakened immune system, are pregnant, or are of Filipino or African heritage, and you develop the signs and symptoms of valley fever, especially if you:

• Live in or have recently traveled to an area where this disease is common
• Have symptoms that aren’t improving

Be sure to tell your doctor if you’ve traveled to a place where valley fever is common and you have symptoms.

Causes

Valley fever is caused by a person inhaling spores of certain fungi. The fungi that cause valley fever — Coccidioides immitis or Coccidioides posadasii — live in the soil in parts of Arizona, Nevada, Utah, New Mexico, California, Texas and Washington. It’s named after the San Joaquin Valley in California. The fungi can also often be found in northern Mexico and Central and South America.

Like many other fungi, coccidioides species have a complex life cycle. In the soil, they grow as a mold with long filaments that break off into airborne spores when the soil is disturbed. A person can then inhale the spores.

The spores are extremely small and can be carried far by the wind. Once inside the lungs, the spores reproduce, continuing the disease cycle.

Risk factors

Risk factors for valley fever include:

• Environmental exposure. Anyone who inhales the spores that cause valley fever is at risk of infection. People who live in areas where the fungi are common — especially those who spend a lot of time outdoors — have a greater risk.

  Also, people who have jobs that expose them to dust are most at risk — construction, road and agricultural workers, ranchers, archaeologists, and military personnel on field exercises.

• Race. For reasons that aren’t well understood, people of Filipino and African heritage are more susceptible to developing serious fungal infections.
• Pregnancy. Pregnant women are vulnerable to more-serious infections when they get the infection during the third trimester. New mothers are vulnerable right after their babies are born.
• Weakened immune system. Anyone with a weakened immune system is at increased risk of serious complications. This includes people living with acquired immunodeficiency syndrome (AIDS) or those being treated with steroids, chemotherapy and anti-rejection drugs after transplant surgery. People with certain autoimmune diseases, such as rheumatoid arthritis or Crohn’s disease, who are being treated with anti-tumor necrosis factor (TNF) drugs also have an increased risk of infection.
• Diabetes. People with diabetes may have a higher risk of severe lung infections.
• Age. Older adults are more likely to develop valley fever. This may be because their immune systems are less robust or because they have other medical conditions that affect their overall health.

Complications

Some people, especially pregnant women, people with weakened immune systems — such as those living with human immunodeficiency virus (HIV)/AIDS — and those of Filipino or African heritage are at risk of developing a more severe form of coccidioidomycosis.

Complications of coccidioidomycosis may include:

• Severe pneumonia. Most people recover from coccidioidomycosis-related pneumonia without complications. Others, such as people of Filipino and African heritage, and those with weakened immune systems, may become seriously ill.
• Ruptured lung nodules. A small percentage of people develop thin-walled nodules (cavities) in their lungs. Many of these eventually disappear without causing any problems, but some may rupture, causing chest pain and difficulty breathing. A ruptured lung nodule might require the placement of a tube into the space around the lungs to remove the air or surgery to repair the damage.
• Disseminated disease. This is the most serious complication of coccidioidomycosis but it’s uncommon. If the fungus spreads (disseminates) throughout the body, it can cause problems including skin ulcers, abscesses, bone lesions, severe joint pain, heart inflammation, urinary tract problems and meningitis — a potentially fatal infection of the membranes and fluid covering the brain and spinal cord.

Prevention

There is no vaccine to prevent valley fever.

If you live in or visit areas where valley fever is common, take common-sense precautions, especially during the dry season following a rainy season when the chance of infection is highest.

Consider these tips:

• Wear a mask.
• Avoid very dusty areas, such as construction sites.
• Stay inside during dust storms.
• Wet the soil before digging in it, or avoiding soil if you’re at higher risk of infection.
• Keep doors and windows tightly closed.
• Clean skin injuries with soap and water.

US drought resurrects fungus that causes fever and meningitis

09/02/2022 at 19:15

Society

2862

Share

Photo: Global Look Press

Fires, floods and the record sting of 2022 certainly pose a great danger to human health. But dry weather in the United States in California has brought to life a disease-causing fungus that spreads by airborne droplets.

It’s called Coccidioides, and it causes Valley Fever. Its symptoms are crushing headaches and sinus infections. Worst of all, it can turn into meningitis.

Former financial planner and father of two, Rob Purry, first contracted a fever and then contracted meningitis. He complained that the illness had taken away all his health and all the money the family had.

Coccidioides requires a dry and hot climate to survive. Therefore, the disease, originally characteristic of the hot plains of California, is becoming more common. This was announced by infectious disease expert Dr. Royce Johnson.

Most of the western US is already in drought, added Morgan Gorris, an Earth system researcher at Los Alamos National Laboratory.

“The western half of the US is still expected to be fairly dry and Valley Fever is expected to spread,” he predicted.

It is important to note that soil, if left undisturbed, will not necessarily lead to inhalation of the disease. But any disturbance to the layer, whether it be a full-scale archaeological site or a burrowing animal, will release the fungus from the soil. Pathogenic spores can travel up to 75 miles (120 km).

Scientists recently warned that the next global pandemic could be fungal. Therefore, the growing spread of Coccidioides is of particular concern.

See also: “The number of cases of monkeypox infection in the world has exceeded 50 thousand”

Subscribe

Authors:

• org/Person”>

  Anastasia Kukova

US

What else to read

What to read:More materials

In the regions

• A tourist spoke about a traffic jam in front of the Crimean bridge: even children are being searched

  34512

  Crimea

  photo: MK in Crimea

• British visionaries: APU will enter the Crimea in a month

  11298

  Crimea

  crimea. mk.ru
  photo: MK in Crimea

• Crimean Maldives: how the holiday season goes on the coolest beaches

  Photo

  10825

  Crimea

  Valeria Rudnik, photo by the author

• July 7 is the day of Ivan Kupala, what is possible and what is strictly forbidden to do on a big holiday

  Photo

  9063

  Pskov

• What caused the worst railway accident in Karelia

  Photo

  8843

  Karelia

  Alexander Trubin

• In Novosibirsk, the girl abandoned the child after the betrayal of her husband

  4258

  Novosibirsk

  Daria Melekhova

In the regions:More materials

A rare type of meningitis for which there is no vaccine.

All About Fungal Meningitis

Fungal meningitis is an inflammation and infection of the membranes surrounding the brain and spinal cord.

There are different types of meningitis, including viral, bacterial and fungal. Of these, the latter, for example, is the rarest in the United States.

Fungal meningitis occurs when a fungus that has invaded another area of ​​the body travels to the brain or spinal cord. Various types of fungi can cause fungal meningitis.

Types of fungal meningitis

Fungal meningitis is divided into types according to the type of fungus causing the infection. There are five types of fungal meningitis.

1. Cryptococcus Neoformans

Cryptococcus Neoformans is a type of fungus found throughout the world:

• in soil,
• bird droppings,
• rotting wood.

People can inhale the fungus after being in close contact with soil or other materials that contain it, but most people who are exposed to Cryptococcus neoformans do not get sick. However, it is the most common form of fungal meningitis, accounting for more than 70% of cases of fungal meningitis.

People with weakened immune systems are more likely to have a Cryptococcus neoformans infection, which can present as a lung infection or meningitis, depending on where in the body the infection occurs.

Cryptococcus neoformans infections are particularly common in people with advanced HIV/AIDS.

2. Coccidioides

Coccidioides is a fungus found in the soil of the southwestern United States, Washington State, Mexico, South America and Central America.

Coccidioidosis causes a condition called valley fever, or coccidioidomycosis. Valley fever can affect anyone and can take months to resolve. People with weakened immune systems are more likely to have severe cases, which can include meningitis.

Coccidioides is responsible for approximately 16% of cases of fungal meningitis.

3. Candida

Candida, better known as yeast, is a fungus that occurs naturally in the body but can cause an infection if it grows too fast or gets into an area of ​​the body it shouldn’t – for example, into the meninges.

Some yeast infections, such as vaginal yeast infection or thrush, are localized to one area of ​​the body, but forms of yeast infections or candidiasis can be invasive. Invasive candidiasis can enter the circulatory system and cause symptoms throughout the body.

About 8% of cases of fungal meningitis are associated with candidiasis.

4. Histoplasma

Histoplasma is a fungus found in bird and bat droppings, especially in the Ohio and Mississippi river valleys, although the fungus can be found far beyond this area.

Histoplasm causes an infection called histoplasmosis, which may include meningitis. Anyone can develop histoplasmosis, and in most cases the condition will go away on its own. However, people with suppressed immune systems are more likely to experience severe cases, including meningitis.

About 6% of cases of fungal meningitis are caused by histoplasma.

5. Blastomyces

Blastomyces is a fungus found in decaying leaves and wood, and in moist soil, especially in the Mississippi River Valley, Ohio River Valley, and Great Lakes regions of the United States.

Blastomycetes can cause an infection called blastomycosis. In most cases, there are no symptoms. However, this type of fungal meningitis is rare.

Symptoms of fungal meningitis

The symptoms of fungal meningitis are the same as the general symptoms of meningitis. These include fever, headache, and neck stiffness, especially when they occur at all. However, the temperature can be below 37.7°C, making it difficult to detect.

Other common symptoms of meningitis include:

• Pain
• Fatigue, drowsiness and trouble waking up
• Lack of appetite
• Nausea and vomiting
• Irritability and mood changes

Causes of fungal meningitis

Fungal meningitis occurs when a person is exposed to a fungus (usually by inhaling it), which then causes an infection in the body. Living in areas exposed to harmful fungi can increase your risk of contracting fungal meningitis. However, people with underlying medical conditions or weakened immune systems are most at risk.

Risk factors

People with weakened immune systems are more likely to get fungal meningitis, as mentioned above. A weakened immune system may be due to:

• Health conditions such as HIV or cancer
• Medicines such as steroids, immunosuppressants and TNF inhibitors
• Various health conditions
• Premature babies are also at higher risk of fungal infections, especially Candida.

Diagnosis

If meningitis is suspected, the doctor will order a blood test and a lumbar puncture, in which cerebrospinal fluid is removed from the spine. Using these samples, the doctor will be able to determine the cause of the infection. This is especially important in the case of fungal meningitis, as the type of fungus you are exposed to will determine the course of treatment.

Treatment of fungal meningitis

Antifungal drugs will be used to treat fungal infections of the nervous system, including fungal meningitis.